[Contributor name pending]

This entry is a structural placeholder for a PhD-level gerontologist or geroscience researcher whose expertise centers on the biology of aging and the role of NAD+ in age-related decline. On assignment, the contributor filling this slot will hold primary review responsibility for content that connects NAD+ biology to the broader aging literature. Typical review scope includes: the age-associated decline of tissue NAD+ levels and its methodological caveats (which tissues, which assays, which populations); the hallmarks of aging framework and where NAD+-dependent processes fit within it; mitochondrial dysfunction, senescence, and stem cell exhaustion as they intersect with NAD+ availability; healthspan versus lifespan endpoint distinctions in both preclinical models and human cohort studies; translational evidence from model organisms (yeast, worm, fly, mouse) and the reproducibility caveats on each; and the interpretation of epigenetic clock and biological age biomarkers used to evaluate NAD+ interventions. The contributor is also responsible for flagging where marketing narratives about “reversing aging” outrun the actual evidence base, particularly on /benefits pages and in blog content covering longevity-adjacent topics. Credentials, institutional affiliation, ORCID, and publication history will be added when a named individual is assigned. Until then, articles requiring gerontology-domain review default to the editorial-team collective byline.

Areas of expertise